We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

115 hedge funds and large institutions have $200M invested in TG Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 43 increasing their positions, 27 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more call options, than puts

Call options by funds: $4.51M | Put options by funds: $2.2M

59% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 27

1.42% more ownership

Funds ownership: 57.56% → 58.98% (+1.4%)

9% less funds holding

Funds holding: 127 → 115 (-12)

25% less capital invested

Capital invested by funds: $267M → $200M (-$66.5M)

41% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 27

Holders
115
Holders Change
-12
Holders Change %
-9.45%
% of All Funds
2.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
43
Reduced
27
Closed
27
Calls
$4.51M
Puts
$2.2M
Net Calls
+$2.3M
Net Calls Change
+$4.13M

Top Buyers

Rank Fund Capital Flow
1
BM
Bridger Management
New York
+$7.96M
2
GPP
Great Point Partners
Connecticut
+$5.22M
3
Two Sigma Investments
Two Sigma Investments
New York
+$2.9M
4
ACA
Avoro Capital Advisors
New York
+$2.73M
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.6M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$10.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$5.36M
3
Bank of America
Bank of America
North Carolina
-$2.9M
4
NC
Nexthera Capital
New York
-$2.49M
5
HCMT
Highland Capital Management (Texas)
Texas
-$1.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$33.6M – – –
ACA
2
Avoro Capital Advisors
New York
$19.5M +$2.73M +549,969 +13%
BlackRock
3
BlackRock
New York
$18.5M +$489K +98,479 +2%
State Street
4
State Street
Massachusetts
$17.8M +$1.03M +206,901 +5%
BM
5
Bridger Management
New York
$15.5M +$7.96M +1,601,446 +73%
GPP
6
Great Point Partners
Connecticut
$12.3M +$5.22M +1,050,000 +54%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$11.2M -$1.1M -221,296 -8%
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.12M -$5.36M -1,078,412 -35%
Credit Agricole
9
Credit Agricole
France
$5.36M -$37.6K -7,572 -0.6%
Renaissance Technologies
10
Renaissance Technologies
New York
$3.59M +$2.6M +523,400 +148%
Deutsche Bank
11
Deutsche Bank
Germany
$3.38M +$723K +145,454 +21%
Northern Trust
12
Northern Trust
Illinois
$3.29M -$104K -20,879 -3%
Two Sigma Investments
13
Two Sigma Investments
New York
$3.15M +$2.9M +582,771 +313%
Goldman Sachs
14
Goldman Sachs
New York
$3.13M +$1.91M +384,274 +102%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$3.1M +$350K +70,398 +10%
CS
16
Candriam SCA
Luxembourg
$2.84M – – –
UBS AM
17
UBS AM
Illinois
$2.7M -$165K -33,292 -5%
Morgan Stanley
18
Morgan Stanley
New York
$2.68M +$2.37M +476,531 +268%
OM
19
Opaleye Management
Massachusetts
$2.25M +$994K +200,000 +57%
Citigroup
20
Citigroup
New York
$2.08M +$1.67M +336,978 +197%
6CM
21
683 Capital Management
New York
$2.05M – – –
HCMT
22
Highland Capital Management (Texas)
Texas
$1.86M -$1.49M -299,791 -40%
AG
23
Artal Group
Luxembourg
$1.64M – – –
UBS Group
24
UBS Group
Switzerland
$1.49M +$1.61M +323,887 +800%
Charles Schwab
25
Charles Schwab
California
$1.43M +$92.3K +18,567 +6%
1
2 3 4 5

TGTX Hedge Fund Activity: Q4 2018 in Review

115 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2018, worth a combined $200M — down 25% from $267M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of TGTX and 16 opened new positions — a net loss of 11 holders — while 27 trimmed existing stakes and 43 added.

The largest buyer was Bridger Management, adding an estimated $7.96M. The largest seller was Franklin Resources, exiting entirely with an estimated $10.6M sold.

  • 115 institutional investors held TG Therapeutics (TGTX) as of Q4 2018, down from 127 in Q3 2018.
  • Funds reported $200M of TG Therapeutics stock for Q4 2018, down 25% quarter-over-quarter.
  • 16 funds opened new TG Therapeutics positions in Q4 2018 and 27 closed out, a net change of -11 holders.
  • The largest TG Therapeutics buyer in Q4 2018 was Bridger Management, an estimated $7.96M added.
  • The largest TG Therapeutics seller in Q4 2018 was Franklin Resources, an estimated $10.6M sold.

Based on aggregated 13F filings for Q4 2018.